EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Intellia’s in vivo Crispr stays in play, clinically at least
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 – Precision moves quickly to deal with allo disappointment
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
